Anthropic announced on Thursday that it has cut Claude Fable 5's biology fallback rate by approximately 85 percent across its product surfaces, the largest revision to the model's biology safeguards since its June 9 launch. The update, published on August 7, gives patients, students, and healthcare clinicians direct access to Fable 5's reasoning on health questions, including interpreting blood test results, understanding disease symptoms, studying cellular biology, and clinical support tasks. However, professional researchers remain unable to use the model for virology, toxicology, or drug development work, with no arrival date given for the access pathway Anthropic promised two months ago. The update arrived one day after Stanford University and the Arc Institute published findings in Science showing that genome language models Evo 1 and Evo 2 had designed 16 functional viral genomes from scratch, the first AI-designed viruses confirmed to replicate in a laboratory setting. A companion editorial from Johns Hopkins biosecurity specialists warned that governance to manage that capability does not yet exist. Anthropic's announcement did not acknowledge this context. The ripple effect on total fallbacks amounts to a 67 percent reduction on Claude.ai, 55 percent on Cowork, 17 percent on Claude Code, and 7 percent on the Claude API Platform.